Key Points
- Musa Tariq, a Guardant Health director, sold 116 shares on Dec. 17 at an average price of $101.46 for about $11,769, reducing his stake to 7,993 shares (a 1.43% decrease); he also sold 116 shares in November and October, showing a pattern of repeated small disposals.
- Guardant Health has a market cap of $12.33 billion and a 52‑week range of $29.91–$112.43, reported revenue up 38.5% YoY with an EPS beat last quarter, and has seen multiple analyst price-target increases (e.g., Leerink to $155, Morgan Stanley to $130) with a consensus Moderate Buy target of $95.52.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of the business's stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $101.46, for a total transaction of $11,769.36. Following the sale, the director directly owned 7,993 shares of the company's stock, valued at approximately $810,969.78. The trade was a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Musa Tariq also recently made the following trade(s):
- On Wednesday, November 19th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $96.25, for a total transaction of $11,165.00.
- On Friday, October 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $66.95, for a total value of $7,766.20.
Guardant Health Stock Performance
Shares of GH stock opened at $97.80 on Friday. The firm has a market cap of $12.33 billion, a price-to-earnings ratio of -30.46 and a beta of 1.58. The firm's 50-day simple moving average is $91.51 and its two-hundred day simple moving average is $67.00. Guardant Health, Inc. has a 52 week low of $29.91 and a 52 week high of $112.43.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same quarter in the previous year, the company posted ($0.88) earnings per share. Guardant Health's revenue for the quarter was up 38.5% compared to the same quarter last year. Analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.
Analysts Set New Price Targets
GH has been the topic of several research analyst reports. Leerink Partners upped their price objective on shares of Guardant Health from $115.00 to $155.00 and gave the stock an "outperform" rating in a research report on Monday. Morgan Stanley boosted their target price on Guardant Health from $105.00 to $130.00 and gave the stock an "overweight" rating in a research report on Monday, December 1st. Stifel Nicolaus set a $73.00 price objective on Guardant Health in a report on Thursday, September 25th. Barclays increased their target price on shares of Guardant Health from $85.00 to $120.00 and gave the stock an "overweight" rating in a report on Monday. Finally, William Blair reaffirmed an "outperform" rating on shares of Guardant Health in a research note on Thursday, September 25th. Twenty-three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $95.52.
Read Our Latest Analysis on GH
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GH. Signaturefd LLC increased its position in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock valued at $33,000 after purchasing an additional 213 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company's stock worth $33,000 after purchasing an additional 334 shares in the last quarter. Allworth Financial LP raised its holdings in Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company's stock worth $37,000 after purchasing an additional 552 shares during the period. Sound Income Strategies LLC bought a new stake in Guardant Health during the third quarter valued at about $38,000. Finally, Optiver Holding B.V. increased its position in Guardant Health by 153.5% in the third quarter. Optiver Holding B.V. now owns 768 shares of the company's stock worth $48,000 after buying an additional 465 shares in the last quarter. Institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
